Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IGFBP2 expression predicts IDH-mutant glioma patient survival.

Oncotarget - 3 Jan 2017

Huang Lin Eric, Cohen Adam L, Colman Howard, Jensen Randy L, Fults Daniel W, Couldwell William T

Abstract excerpt

Mutations of the isocitrate dehydrogenase (IDH) 1 and 2 genes occur in ~80% of lower-grade (WHO grade II and grade III) gliomas. Mutant IDH produces (R)-2-hydroxyglutarate, which induces DNA hypermethylation and presumably drives tumorigenesis. Interestingly, IDH mutations are associated with improved survival in glioma patients, but the underlying mechanism for the difference in survival remains unclear. Through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Databases, Nucleic Acid
Share to Glioma
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Neurofibromin 1

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 27852048
DOI: 10.18632/oncotarget.13329
PMCID: PMC5352106

Genes

IGFBP2
AKT2
ARAF
ERBB2
FGFR3
FOXM1
PDGFRB
PTEN
WWTR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IGFBP2 expression predicts IDH-mutant glioma patient survival.PMID 27852048Read ↗

From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.Semantic proximity Read ↗

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors.Semantic proximity Read ↗

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Semantic proximity Read ↗

Molecular classification of IDH-mutant glioblastomas based on gene expression profilesSemantic proximity Read ↗

Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.Semantic proximity Read ↗

RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma.Semantic proximity Read ↗

Tumor Mutational Burden Predicts Survival In Patients With Low Grade Gliomas Expressing Mutated IDH1Semantic proximity Read ↗

IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.Semantic proximity Read ↗

Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.Semantic proximity Read ↗

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Semantic proximity Read ↗

A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.